TY - JOUR
T1 - Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents
AU - Fucikova, Jitka
AU - Palova-Jelinkova, Lenka
AU - Klapp, Vanessa
AU - Holicek, Peter
AU - Lanickova, Tereza
AU - Kasikova, Lenka
AU - Drozenova, Jana
AU - Cibula, David
AU - Álvarez-Abril, Beatriz
AU - García-Martínez, Elena
AU - Spisek, Radek
AU - Galluzzi, Lorenzo
N1 - Funding Information:
L.G. is supported by a Breakthrough Level 2 grant from the US Department of Defense (DoD) Breast Cancer Research Program (BRCP) (# BC180476P1 ), by the 2019 Laura Ziskin Prize in Translational Research [#ZP-6177, Principal Investigator (PI): Formenti] from Stand Up to Cancer (SU2C), by a Mantle Cell Lymphoma Research Initiative (MCL-RI, PI: Chen-Kiang) grant from the Leukemia and Lymphoma Society (LLS), by a startup grant from the Department of Radiation Oncology at Weill Cornell Medicine, by a Rapid Response Grant from the Functional Genomics Initiative, by industrial collaborations with Lytix Biopharma and Phosplatin, and by donations from Phosplatin, the Luke Heller TECPR2 Foundation, Sotio Biotech, Onxeo, and Noxopharm.
Funding Information:
L.G. is supported by a Breakthrough Level 2 grant from the US Department of Defense (DoD) Breast Cancer Research Program (BRCP) (#BC180476P1), by the 2019 Laura Ziskin Prize in Translational Research [#ZP-6177, Principal Investigator (PI): Formenti] from Stand Up to Cancer (SU2C), by a Mantle Cell Lymphoma Research Initiative (MCL-RI, PI: Chen-Kiang) grant from the Leukemia and Lymphoma Society (LLS), by a startup grant from the Department of Radiation Oncology at Weill Cornell Medicine, by a Rapid Response Grant from the Functional Genomics Initiative, by industrial collaborations with Lytix Biopharma and Phosplatin, and by donations from Phosplatin, the Luke Heller TECPR2 Foundation, Sotio Biotech, Onxeo, and Noxopharm. J.F. conceived the article and wrote the first version of the manuscript under the supervision of R.S. and L.G. with critical conceptual and writing input from all authors. J.F. and V.K. prepared display items under supervision of L.G. All authors approved the final version of the article. J.F. and R.S. are full-time employees of Sotio Biotech. I.V. has received consulting/advisory honoraria from AstraZeneca, Clovis Oncology Inc. Carrick Therapeutics, Deciphera Pharmaceuticals, Elevar Therapeutics, Roche, Genmab, GSK, Immunogen, Jazzpharma, Mersana, Millennium Pharmaceuticals, MSD, Novocure, Octimet Oncology, Oncoinvent, Sotio, Verastem Oncology, and Zentalis; and has performed contracted research for Amgen, Genmab, Oncoinvent, and Genmab. E.G.M. has held research contracts with Roche, has received consulting/advisory honoraria from AstraZeneca and Clovis, as well as speaker honoraria from GSK, AstraZeneca, MSD, Clovis, and Roche. L.G. has held research contracts with Lytix Biopharma and Phosplatin, and has received consulting/advisory honoraria from Boehringer Ingelheim, AstraZeneca, OmniSEQ, Onxeo, Sotio, The Longevity Labs, Inzen, and the Luke Heller TECPR2 Foundation. All other authors have no conflicts to declare.
Publisher Copyright:
© 2022 Elsevier Inc.
PY - 2022/5
Y1 - 2022/5
N2 - At odds with other solid tumors, epithelial ovarian cancer (EOC) is poorly sensitive to immune checkpoint inhibitors (ICIs), largely reflecting active immunosuppression despite CD8+ T cell infiltration at baseline. Accumulating evidence indicates that both conventional chemotherapeutics and targeted anticancer agents commonly used in the clinical management of EOC not only mediate a cytostatic and cytotoxic activity against malignant cells, but also drive therapeutically relevant immunostimulatory or immunosuppressive effects. Here, we discuss such an immunomodulatory activity, with a specific focus on molecular and cellular pathways that can be harnessed to develop superior combinatorial regimens for clinical EOC care.
AB - At odds with other solid tumors, epithelial ovarian cancer (EOC) is poorly sensitive to immune checkpoint inhibitors (ICIs), largely reflecting active immunosuppression despite CD8+ T cell infiltration at baseline. Accumulating evidence indicates that both conventional chemotherapeutics and targeted anticancer agents commonly used in the clinical management of EOC not only mediate a cytostatic and cytotoxic activity against malignant cells, but also drive therapeutically relevant immunostimulatory or immunosuppressive effects. Here, we discuss such an immunomodulatory activity, with a specific focus on molecular and cellular pathways that can be harnessed to develop superior combinatorial regimens for clinical EOC care.
KW - antiangiogenic agents
KW - bevacizumab
KW - immunogenic cell death
KW - PARP inhibitors
KW - platinum derivatives
KW - taxanes
UR - http://www.scopus.com/inward/record.url?scp=85124669793&partnerID=8YFLogxK
U2 - 10.1016/j.trecan.2022.01.010
DO - 10.1016/j.trecan.2022.01.010
M3 - Review article
C2 - 35181272
AN - SCOPUS:85124669793
SN - 2405-8033
VL - 8
SP - 426
EP - 444
JO - Trends in Cancer
JF - Trends in Cancer
IS - 5
ER -